CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific advisory board (SAB).
“Surface Oncology continues to grow and learn as a company and we look to align ourselves with world-class leaders in the fields of oncology and immunology. Steve is a clinical pioneer in the field of cancer immunotherapy. His groundbreaking work in melanoma with checkpoint inhibitors led to the first wave of cancer immunotherapy drug approvals. We are thrilled Steve has agreed to join our world-class scientific advisory board and look forward to his clinical and scientific insights,” said Vito Palombella PhD, chief scientific officer of Surface Oncology.
Dr. Hodi is Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College. Dr. Hodi completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania, and Medical Oncology training at Dana-Farber Cancer Institute. His research focuses on the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, and a founding member of the Society for Melanoma Research.
“I am excited to have the opportunity to collaborate with the team at Surface Oncology. Surface’s goal of targeting the immunosuppressive tumor microenvironment has produced a unique portfolio of programs,” said Dr. Hodi. “I look forward to working with the team to help move these programs through clinical development, identify additional novel targets to pursue, and to make a meaningful impact for patients.”
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
For more information, please visit www.surfaceoncology.com
Ten Bridge Communications
Source: Surface Oncology, Inc.